FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
The reach of the Indian pharmaceutical industry is enormous. India supplies a large and increasing amount of the generic drugs sold globally, and the country is home to over 150 drug manufacturing facilities approved by the US Food and Drug Administration1—including many run by multinational players.
The basic challenge faced by medical products companies is that they’re trying to sell expensive products into an environment that’s increasing concerned about the cost of care, and in which key stakeholders are aggressively looking for opportunities to bring the costs down, and avoid unnecessary expenditures.
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.
As drug companies take divergent strategies focused either on research or cutting costs, what might this mean for the path future companies take in the pharmaceutical industry?
High-profile technology companies are revered by society while pharmaceutical companies developing life-saving technologies are viewed with contempt; why the disparity?
The tragic deaths of 55 Americans and sickening of more than 740, resulting from contaminated steroid injections that were shipped by a disreputable firm in Massachusetts, have rightly focused public attention on a largely unfamiliar, but prominent part of our drug supply chain – the practice of pharmacy compounding.
Scott Gottlieb's testimony for the House Energy and Commerce Committee, Subcommittee on Health's hearing on drug compounding.
The Shadow Financial Regulatory Committee (SFRC) is a group of publicly recognized independent experts on the financial services industry — including experts in banking, insurance, and securities — who meet regularly to study and critique regulatory policies affecting this sector of the economy.
This event has been cancelled due to inclement weather.
At a Capitol Hill luncheon event, Westchester County Executive, Robert Astorino, will present his first-hand experience with HUD's demands to sue localities over common zoning regulations in an effort to dismantle local zoning as it is known today.
AEI's Marilyn Ware Center for Security Studies will host General Mark Welsh III, Chief of Staff of the US Air Force for the concluding session of its series with the Joint Chiefs of Staff.
Join AEI for a discussion of two new policy proposals that address the use of road pricing and public-private partnerships, as well as state efforts to enhance infrastructure and economic competitiveness.
Join AEI for a discussion of professional sports subsidies and — fittingly — for a free lunch.
AEI’s Jeffrey Eisenach will argue in favor of a generic antitrust enforcement model with primary enforcement by the FTC and Jonathan Baker of American University will maintain that an industry-specific regulator like the FCC is needed to work with antitrust enforcers to shape competition in the broadband industry. The debate will be moderated by US Court of Appeals Judge Stephen Williams.